Yun Zhang1, Mingming Liang1, Chenyu Sun2, Guangbo Qu1, Tingting Shi1, Min Min1, Yile Wu3, Yehuan Sun. 1. From the Department of Epidemiology and Health Statistics, School of Public Health, and. 2. Center for Evidence-Based Practice, Anhui Medical University. 3. Department of Hospital Infection Prevention and Control, the Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Abstract
OBJECTIVE: The aim of this study was to explore the relationship between statin use and the risk of pancreatic cancer. METHODS: Electronic databases were searched to identify relevant studies published until January 2018. The pooled relative risks (RRs) and 95% confidence intervals (CIs) were calculated with random-effects model. Subgroup analyses and sensitivity analysis were also conducted. Cochran Q test and I(2) statistic were used to evaluate the heterogeneity. RESULTS: Twenty-six studies were included that contained more than 3 million participants and 170,000 pancreatic cancer patients. The overall result demonstrated a significant decrease in pancreatic cancer risk with statin use (RR, 0.84; 95% CI, 0.73-0.97; P = 0.000; I(2) = 84.4%). In subgroup analyses, nonsignificant association was detected between long-term statin use and the risk of pancreatic cancer (RR, 0.98; 95% CI, 0.86-1.11; P = 0.718; I(2) = 0.0%). Meanwhile, there was nonsignificant association between the use of lipophilic statins and the risk of pancreatic cancer (RR, 0.98; 95% CI, 0.84-1.15; P = 0.853; I(2) = 27.2%). No publication bias was found in this meta-analysis. CONCLUSIONS: The overall result of this meta-analysis supports the hypothesis that statins have a protective effect on pancreatic cancer. Furthermore, high-quality randomized clinical trials and cohort studies are needed to confirm these findings.
OBJECTIVE: The aim of this study was to explore the relationship between statin use and the risk of pancreatic cancer. METHODS: Electronic databases were searched to identify relevant studies published until January 2018. The pooled relative risks (RRs) and 95% confidence intervals (CIs) were calculated with random-effects model. Subgroup analyses and sensitivity analysis were also conducted. Cochran Q test and I(2) statistic were used to evaluate the heterogeneity. RESULTS: Twenty-six studies were included that contained more than 3 million participants and 170,000 pancreatic cancerpatients. The overall result demonstrated a significant decrease in pancreatic cancer risk with statin use (RR, 0.84; 95% CI, 0.73-0.97; P = 0.000; I(2) = 84.4%). In subgroup analyses, nonsignificant association was detected between long-term statin use and the risk of pancreatic cancer (RR, 0.98; 95% CI, 0.86-1.11; P = 0.718; I(2) = 0.0%). Meanwhile, there was nonsignificant association between the use of lipophilic statins and the risk of pancreatic cancer (RR, 0.98; 95% CI, 0.84-1.15; P = 0.853; I(2) = 27.2%). No publication bias was found in this meta-analysis. CONCLUSIONS: The overall result of this meta-analysis supports the hypothesis that statins have a protective effect on pancreatic cancer. Furthermore, high-quality randomized clinical trials and cohort studies are needed to confirm these findings.
Authors: Shehnaz K Hussain; Asieh Golozar; Daniel P Widney; Giovanna Rappocciolo; Sudhir Penugonda; Jay H Bream; Otoniel Martínez-Maza; Lisa P Jacobson Journal: AIDS Res Hum Retroviruses Date: 2020-12-29 Impact factor: 1.723
Authors: Joseph W Franses; Julia Philipp; Pavlos Missios; Irun Bhan; Ann Liu; Chittampalli Yashaswini; Eric Tai; Huili Zhu; Matteo Ligorio; Benjamin Nicholson; Elizabeth M Tassoni; Niyati Desai; Anupriya S Kulkarni; Annamaria Szabolcs; Theodore S Hong; Andrew S Liss; Carlos Fernandez-Del Castillo; David P Ryan; Shyamala Maheswaran; Daniel A Haber; George Q Daley; David T Ting Journal: Nat Commun Date: 2020-07-03 Impact factor: 14.919
Authors: Yue Chang; Qinyu Liu; Zidong Zhou; Yuping Ding; Mei Yang; Wei Xu; Kai Chen; Qing Zhang; Zhenguo Wang; Hai Li Journal: Technol Cancer Res Treat Date: 2020 Jan-Dec
Authors: Tobiloba E Oni; Giulia Biffi; Lindsey A Baker; Yuan Hao; Claudia Tonelli; Tim D D Somerville; Astrid Deschênes; Pascal Belleau; Chang-Il Hwang; Francisco J Sánchez-Rivera; Hilary Cox; Erin Brosnan; Abhishek Doshi; Rebecca P Lumia; Kimia Khaledi; Youngkyu Park; Lloyd C Trotman; Scott W Lowe; Alexander Krasnitz; Christopher R Vakoc; David A Tuveson Journal: J Exp Med Date: 2020-09-07 Impact factor: 14.307